资讯
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
1 天
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Pfizer Inc. today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT, evaluating two doses of ABRYSVO vaccine in ...
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
The approval makes Pfizer’s Abrysvo the first RSV vaccine indicated for adults younger than 50, the company said. Photo: Carlo Allegri/REUTERS ...
Pfizer’s RSV vaccine Abrysvo in the manufacturing process. But a rival RSV shot, GSK’s Arexvy, got off to a better start. To catch up, Pfizer overhauled how it packages, ...
NEW YORK, August 12, 2024--Pfizer Inc. ... Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults. Business Wire . Mon, Aug 12, 2024, 6:45 AM 11 min read.
In August 2023, Pfizer announced that the European Commission granted marketing authorization for ABRYSVO for both adults aged 60 years and older and maternal immunization to help protect infants.
Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study ...
Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果